Biomarker directed therapies in biliary tract cancers

Approximately 40% of biliary tract cancer harbor gene alterations that can be targeted with precision-based medicines. James J. Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the targetable mutations in biliary tract cancer and the future of the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.